<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313842</url>
  </required_header>
  <id_info>
    <org_study_id>2018-12-071</org_study_id>
    <nct_id>NCT04313842</nct_id>
  </id_info>
  <brief_title>A Explorative Study to Evaluate the Clinical Feasibility of AVATAMED</brief_title>
  <official_title>A Clinical Study to Explore the Feasibility of AVATAMED in Predicting the Cilnical Response to Temozolomide in Glioblastoma Patients, a Single-center, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Doo-Sik Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study to evaluate the clinical feasibility of medical deivce
      'AVATAMED' for predicting the clinical response to TMZ (temozolomide) in glioblasotma
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma patients who would take TMZ treatment will be screened for in vitro drug
      screening experiment. Patients whose tumor specimen pass the drug screening process will be
      finally enrolled.

      Actual clinical response to TMZ treatment will be compared to drug screening results derived
      from AVATAMED, a medical software device to predict the drug response based on in vitro assay
      using patient-derived tumor cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6 month PFS rate</measure>
    <time_frame>6 month</time_frame>
    <description>the fraction of patients without disease progression at 6 months after the TMZ treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVATAMED</intervention_name>
    <description>tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        among histologically confirmed glioblastoma patients, patients with samples which passed
        the QC screening process of in vitro drug screening experiment will be finally enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent

          2. histologically confirmed glioblastoma patients who will take TMZ treatment

          3. KPS &gt;70

          4. adequte end-organ function

          5. prior major surgery &gt; 4 weeks (prior minor surgery &gt; 1weeks)

          6. prior standard concurrent chemo-radiation therapy &gt; 4 weeks

          7. prior radiation therapy (including stereotactic radiosurgery) &gt; 12 weeks

        Exclusion Criteria:

          1. contraindication to TMZ

          2. prior anti-cancer therapy except standard of care (*standard of care includes surgery,
             Stupp regimen, and radiotherapy)

          3. uncontrolled systemic medical illness

          4. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo-sik Kong, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doo-sik Kong, MD PhD</last_name>
    <phone>82-2-6182-5036</phone>
    <email>doosik.kong@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-Sik Kong, MD,Ph.D</last_name>
      <phone>+82-2-3410-0732</phone>
      <email>doosik.kong@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doo-Sik Kong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

